Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s ...

The company bought the rights to an experimental cancer drug for $1.3 billion, plus potential milestone payments of $4.8 ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

Pfizer (PFE) stock gains as Braftovi combo shows survival benefits in a late-stage trial for metastatic colorectal cancer ...

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 ...

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.

Adding Pfizer’s cancer drug Braftovi to standard treatments helped people with a form of colorectal cancer live longer without their disease worsening than those who got the typical care alone ...

Pfizer's experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial, the drugmaker said ...

which suppresses the immune system from fighting cancer cells. And although Pfizer's deal is with a China-based company, Pfizer said it plans to manufacture drug substance for SSGJ-7807 in Sanford ...